Collectively, our data demonstrate that the inhibition of ALDH1A1 with a small-molecule inhibitor in combination with chemotherapy could suppress senescence and stemness to improve outcomes for ovarian cancer patients. Here, ALDH1A1 is linked to ovarian cancer.